Genmab As Stock Investor Sentiment

GMAB Stock  USD 19.90  0.24  1.19%   
About 61% of Genmab AS's investor base is looking to short. The analysis of the overall investor sentiment regarding Genmab AS suggests that many traders are alarmed. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.

Comfort Level 39

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Genmab AS's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Genmab AS.
53.0%
15.0%
50.0%

Genmab Historical Sentiment

Although Genmab AS's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Genmab, such as negative comments on social media and news outlets, may cause fear in the market and push Genmab AS's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Genmab.
  

Genmab AS Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Genmab AS can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
49.2%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Genmab AS Historical Investor Sentiment

Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
News FrequencyInvestor Sentiment
Genmab AS's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Genmab AS and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Genmab AS news discussions. The higher the estimate score, the more favorable the investor's outlook on Genmab AS.

Genmab AS Maximum Pain Price Across May 16th 2025 Option Contracts

Genmab AS's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Genmab AS close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Genmab AS's options.
Calls PricePuts Price
19 hours ago at businesswire.com         
Bispecific Antibody Drug Conjugates Outlook 2024-2029 Featuring Alphamab, Amgen, AstraZeneca, Beijin...
businesswire News
a day ago at seekingalpha.com         
Genmab and BridgeBio Pharma announce Japan approval for their treatments
seekingalpha News
a day ago at benzinga.com         
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
benzinga news
2 days ago at thelincolnianonline.com         
Genmab AS Shares Gap Up Heres What Happened
news
few days ago at news.google.com         
Genmab dismisses Abbvie lawsuit - accused of exploiting trade secrets -March 24, 2025 at 0330 am EDT...
Google News at Macroaxis
six days ago at thelincolnianonline.com         
Signaturefd LLC Increases Position in Genmab AS
news
six days ago at gurufocus.com         
Genmab AS Announces Promising Results from RAINFOL-01 Study in Ovarian Cancer
Gurufocus Stories at Macroaxis
over a week ago at insidermonkey.com         
Genmab AS A Bull Case Theory
insidermonkey News
over a week ago at finance.yahoo.com         
Genmab AS A Bull Case Theory
Yahoo News
over a week ago at thelincolnianonline.com         
Genmab AS Short Interest Down 23.5 percent in February
news
over a week ago at finance.yahoo.com         
Investigational Rinatabart Sesutecan Continues to Show Encouraging Antitumor Activity in Patients wi...
Yahoo News
over a week ago at finance.yahoo.com         
Investigational Rinatabart Sesutecan Continues to Show Encouraging Antitumor Activity in Patients wi...
Yahoo News
over a week ago at businesswire.com         
Investigational Rinatabart Sesutecan Continues to Show Encouraging Antitumor Activity in Patients wi...
businesswire News
over two weeks ago at finance.yahoo.com         
Constitution of the Board of Directors in Genmab AS, Grant of Restricted Stock Units to Board Member...
Yahoo News
over two weeks ago at finance.yahoo.com         
Passing of Genmab AS Annual General Meeting
Yahoo News
Far too much social signal, news, headlines, and media speculation about Genmab AS that are available to investors today. That information is available publicly through Genmab media outlets and privately through word of mouth or via Genmab internal channels. However, regardless of the origin, that massive amount of Genmab data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genmab AS news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genmab AS relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genmab AS's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genmab AS alpha.

Genmab AS Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789102025FebMar -505101520
JavaScript chart by amCharts 3.21.15Genmab AS Genmab AS Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
01/03/2025
2
Genmab AS Reaches New 52-Week Low Time to Sell
01/29/2025
3
Transactions with shares and linked securities in Genmab AS made by managerial employees and their closely associated persons
03/04/2025
4
Genmab Announces Johnson Johnson Decision Regarding HexaBody-CD38
03/10/2025
5
Truist Financial Cuts Genmab AS Price Target to 45.00
03/11/2025
6
Constitution of the Board of Directors in Genmab AS, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
03/12/2025
7
Investigational Rinatabart Sesutecan Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
03/17/2025
8
Genmab AS A Bull Case Theory
03/19/2025
9
Signaturefd LLC Increases Position in Genmab AS
03/21/2025
10
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
03/27/2025

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk